Table 4.

Risks of advanced colorectal adenoma associated with EPHX1 genotypes and cigarette smoking in the PLCO Cancer Screening Trial

No tobacco
Long-term quitters (quit ≥10 years)
Current or recent smokers (quit <10 years)


All
Light (≤20 cigarettes/d)
Heavy (>20 cigarettes/d)
OR (95% CI), case/control (n)OR (95% CI), case/control (n)OR (95% CI), case/control (n)OR (95% CI), case/control (n)OR (95% CI), case/control (n)
Combined number of 113Tyr or 139Arg alleles
0-1 (low)1.0, 84/1151.3 (0.9-2.0), 89/932.2 (1.3-3.6), 56/402.6 (1.4-4.8), 34/201.7 (0.9-3.4), 22/20
2 (medium)1.2 (0.8-1.8), 96/1661.2 (0.8-1.7), 107/1322.3 (1.4-3.7), 71/482.5 (1.4-4.4), 42/272.1 (1.1-4.0), 29/21
3-4 (high)1.3 (0.9-2.0), 80/841.4 (0.9-2.2), 76/774.7 (2.7-8.3), 71/234.1 (2.0-8.3), 35/135.6 (2.6-12.1), 36/10
OR (95% CI) for 3-4 versus 0-1 high-activity alleles in smoking subgroup1.3 (0.9-2.1)1.1 (0.7-1.6)2.2 (1.2-4.2)1.6 (0.7-3.8)3.3 (1.3-8.7)
Ptrend in smoking subgroup0.21.00.020.30.02
  • NOTE: Adjusted for gender, race, and age. Subjects who never used cigarettes but used pipes or cigars were excluded. Pinteraction = 0.06 between the EPHX1 combined genotype (3-4 versus 0-2 high–activity alleles) and smoking status (current or recent smokers versus long-term quitters or nonsmoker).